Navigation Links
Mayo Clinic Proceedings: Gabapentin opens window of communication
Date:6/16/2010

ROCHESTER, Minn. -- For patients with quadriplegia, mutism and lower cranial nerve paralysis (locked-in syndrome), their only means of interacting with others is through vertical gaze and upper eyelid movements, using eye-coded communication strategies.

In the June issue of Mayo Clinic Proceedings, researchers from Italy describe four patients with locked-in syndrome who also had dancing eye syndrome (opsoclonus-myoclonus syndrome). Because these patients' eyes spontaneously and continuously oscillated in a variety of directions beyond their control, they could no longer interact with family members, physicians or other people.

The lead author, Francesca Pistoia, M.D., University of L'Aquila, Italy, reports that a decision was made to treat these patients with daily continuous gabapentin therapy based on a previous successful experience. Gabapentin was started as a single 300 mg dose on the first day followed by 600 milligrams per day in divided doses on the second day. In two of the patients, this dosage reduced ocular symptoms, and communication and quality of life improved. For the other two patients, the dose was further increased, with the best response achieved with a daily 1,200 mg dose.

In all four patients, attempts to stop treatment resulted in recurrence of dancing eye symptoms six hours after the last dose. Thus, gabapentin use was promptly resumed. Researchers found none of the patients experienced adverse effects from the treatment.

In an accompanying editorial, Joseph Sirven, M.D., Mayo Clinic neurologist, discusses the off-label use of gabapentin, which was approved by the U.S. Food and Drug Administration in 1994 for use as an adjunctive medication to control partial seizures. Dr. Sirven writes, "Ironically, despite the fact that the drug was invented and synthesized for its use in seizure prevention, its smallest market today is epilepsy and seizures."

"The study by Pistoia and colleagues has a potential profound impact for treatment of patients with locked-in syndrome and opsoclonus-myoclonus syndrome," writes Dr. Sirven. "Because this neurologic condition is so rare, small observational studies serve as the main source of clinical evidence and could be the cornerstone for clinical practice with no other evidence."


'/>"/>

Contact: Rebecca Finseth
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. BRAF inhibitor shows promising preclinical activity against melanoma
2. Free Clinics Play Important Role for Uninsured in U.S.
3. Sunrise Services Wins the Gold in Medisoft Clinical Sales Contest
4. Sanford Health Announces Sanford Children's Clinic in Klamath Falls, OR
5. Sharron Davies opens new respiratory research clinic
6. European patient survey add weight to expert call for greater clinical consensus on BTCP
7. FDA approves first human neural stem cell clinical trial to treat brain tumors
8. Antibody therapy lengthens survival of metastatic melanoma patients in large clinical trial
9. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
10. Fox Chase clinical trial tests first of its kind antibody
11. Launching Five Clinics on Wheels This Year, Ronald McDonald House Charities Celebrates Ten Years of the Ronald McDonald Care Mobile Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... York, NY (PRWEB) , ... March 24, 2017 ... ... global scale; from third world countries to hospitals in the United States, it’s ... a conversation on the current obstacles facing infection prevention and offers strategies for ...
(Date:3/24/2017)... , ... March 24, 2017 , ... The iaedp Foundation, ... other medical professionals caring for those suffering from the full spectrum of disordered eating, ... as eating disorders professionals from nearly all 50 states and several countries converged on ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Assili, announce that they are now offering treatments for sleep apnea and TMJ ... dental offices. Sleep apnea , specifically the obstructive type, is increasingly being ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, ... their training and leads programs. , In February, 2017, Empower Brokerage introduced their ... Performance Partners is designed to teach how to maximize their sales efforts, as ...
(Date:3/24/2017)... ... , ... “The Communion of Saints: A Pastor’s Potpourri of ... across the United States. “The Communion of Saints” is the creation of ... congregations in seven states throughout his long career of devotion to the church. ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)...   The Accreditation Council for Medical Affairs ... the pharmaceutical industry has appointed Dr. Jane ... formed scientific advisory board. Dr. Chin will be ... ever medical affairs think tank within the pharmaceutical ... ACMA, please visit  www.medicalaffairsspecialist.org .  Connect with ...
(Date:3/24/2017)... 24, 2017 FinancialBuzz.com News Commentary  ... According to ... cannabis market research, the legal cannabis market is projected to ... despite conflicting signals from the current presidential administration. The report ... two biggest drivers of growth in this industry are the ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... to their offering. ... IPF pipeline is very strong with a total of 97 drug candidates. ... and Sanofi are involved in the development of the IPF therapeutics. The ... Phase III stage, 15 are in Phase II stage, 12 are in ...
Breaking Medicine Technology: